Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
Celularity (CELU) faces potential delisting from Nasdaq due to two separate issues. First, the company failed to pay required fees of $70,000 under Listing Rule 5250(f), which was subsequently paid in full on April 25, 2025. Second, Nasdaq notified the company on April 16, 2024, about its delinquency in filing the Form 10-K for the year ended December 31, 2024, violating Listing Rule 5250(c)(1).
If Celularity doesn't appeal these determinations, trading of its common stock will be suspended on May 1, 2025. The company must address both compliance issues before a Hearings Panel if it appeals. Celularity states it is actively working on filing the 2024 Form 10-K and expects to complete it imminently.
Celularity (CELU) rischia la rimozione dal Nasdaq a causa di due problemi distinti. In primo luogo, la società non ha pagato le commissioni richieste di 70.000 $ secondo la Regola di Quotazione 5250(f), somma poi saldata integralmente il 25 aprile 2025. In secondo luogo, il Nasdaq ha notificato alla società il 16 aprile 2024 il ritardo nella presentazione del Modulo 10-K relativo all'anno chiuso il 31 dicembre 2024, violando la Regola di Quotazione 5250(c)(1).
Se Celularity non presenterà ricorso contro queste decisioni, la negoziazione delle sue azioni ordinarie sarà sospesa a partire dal 1 maggio 2025. La società dovrà risolvere entrambe le questioni di conformità davanti a un Panel di Udienza in caso di appello. Celularity dichiara di essere attivamente impegnata nella preparazione del Modulo 10-K 2024 e prevede di completarlo a breve.
Celularity (CELU) enfrenta una posible exclusión del Nasdaq debido a dos problemas distintos. Primero, la empresa no pagó las tarifas requeridas de 70,000 $ según la Regla de Listado 5250(f), que fue abonada en su totalidad el 25 de abril de 2025. Segundo, Nasdaq notificó a la compañía el 16 de abril de 2024 sobre su incumplimiento en presentar el Formulario 10-K correspondiente al año finalizado el 31 de diciembre de 2024, violando la Regla de Listado 5250(c)(1).
Si Celularity no apela estas determinaciones, la negociación de sus acciones comunes será suspendida a partir del 1 de mayo de 2025. La empresa debe resolver ambos problemas de cumplimiento ante un Panel de Audiencias si decide apelar. Celularity afirma que está trabajando activamente en la presentación del Formulario 10-K 2024 y espera completarlo pronto.
Celularity (CELU)는 두 가지 문제로 인해 나스닥 상장 폐지 가능성에 직면해 있습니다. 첫째, 회사는 상장 규칙 5250(f)에 따른 70,000달러의 필수 수수료를 납부하지 않았으나, 2025년 4월 25일에 전액 납부하였습니다. 둘째, 나스닥은 2024년 4월 16일에 2024년 12월 31일 종료된 연도에 대한 Form 10-K 제출 지연을 통지했으며, 이는 상장 규칙 5250(c)(1)을 위반한 것입니다.
Celularity가 이 결정에 대해 항소하지 않으면, 보통주 거래는 2025년 5월 1일에 중단됩니다. 회사는 항소할 경우 청문회 패널 앞에서 두 가지 준수 문제를 해결해야 합니다. Celularity는 2024년 Form 10-K 제출을 적극 진행 중이며 곧 완료할 것으로 기대하고 있다고 밝혔습니다.
Celularity (CELU) risque une radiation du Nasdaq en raison de deux problèmes distincts. Premièrement, la société n’a pas payé les frais requis de 70 000 $ conformément à la règle de cotation 5250(f), qui ont été réglés intégralement le 25 avril 2025. Deuxièmement, le Nasdaq a informé la société le 16 avril 2024 de son retard dans le dépôt du Formulaire 10-K pour l’exercice clos au 31 décembre 2024, enfreignant la règle de cotation 5250(c)(1).
Si Celularity ne fait pas appel de ces décisions, la négociation de ses actions ordinaires sera suspendue à partir du 1er mai 2025. La société devra résoudre ces deux problèmes de conformité devant un panel d’audience en cas d’appel. Celularity déclare travailler activement à la préparation du Formulaire 10-K 2024 et prévoit de le finaliser sous peu.
Celularity (CELU) steht aufgrund von zwei getrennten Problemen vor einer möglichen Delistung vom Nasdaq. Erstens hat das Unternehmen die erforderlichen Gebühren in Höhe von 70.000 $ gemäß Listing-Regel 5250(f) nicht bezahlt, diese wurden jedoch am 25. April 2025 vollständig beglichen. Zweitens informierte Nasdaq das Unternehmen am 16. April 2024 über die verspätete Einreichung des Formulars 10-K für das am 31. Dezember 2024 endende Jahr, was gegen Listing-Regel 5250(c)(1) verstößt.
Wenn Celularity gegen diese Entscheidungen keinen Einspruch einlegt, wird der Handel mit den Stammaktien ab dem 1. Mai 2025 ausgesetzt. Das Unternehmen muss beide Compliance-Probleme vor einem Anhörungsgremium klären, falls es Einspruch erhebt. Celularity gibt an, aktiv an der Einreichung des 2024er Formulars 10-K zu arbeiten und erwartet, dies in Kürze abzuschließen.
- Paid outstanding Nasdaq fees of $70,000 in full
- Actively working to file delinquent Form 10-K imminently
- Risk of immediate Nasdaq delisting due to compliance violations
- Delinquent in filing 2024 Form 10-K annual report
- Failed to pay required Nasdaq fees on time
- Multiple concurrent listing compliance issues requiring resolution
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees required by Listing Rule 5250(f) and accordingly the Company will be delisted unless it appeals this determination. The Company’s past due fee balance totaled
Additionally, on April 16, 2024, Nasdaq notified the Company that it is delinquent in filing its Form 10-K for the year ended December 31, 2024, and therefore, does not comply with Listing Rule 5250(c)(1). Nasdaq requested the Company to provide a plan of compliance. However, pursuant to Listing Rule 5810(d)(2), this delinquency now serves as an additional and separate basis for delisting, and as such, the Company should address these concerns before a Hearings Panel if it appeals Nasdaq’s determination. If the Company elects not to appeal, then trading of its common stock will be suspended at the opening of business on May 1, 2025.
The Company is actively working to file the 2024 Form 10-K and currently expects to file the 2024 Form 10-K imminently.
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
For more information, visit www.celularity.com.
Forward Looking Statements
This press release includes “forward-looking statements” (as defined under Federal securities laws). All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks,” and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on July 30, 2024, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
FAQ
Why is Celularity (CELU) facing delisting from Nasdaq in 2025?
When will CELU stock be suspended from trading on Nasdaq?
Has Celularity resolved its Nasdaq fee payment issue?
What must Celularity do to maintain its Nasdaq listing?
